Clinical Trial Update: Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial comparing ranibizumab to low-fluence photodynamic therapy for chronic central serous chorioretinopathy completed with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Serous Chorioretinopathy

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Jang Won Heo | Conditions: Chronic Central Serous Chorioretinopathy | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-05-27